In-vitro delivery of BLM into resistant cancer cell line using sonoporation with low-boiling point phase change ultrasound contrast agents

Bleomycin (BLM) is a promising chemotherapeutic that causes oxidative damage to DNA resulting in cell death. However, this non-permeant drug is mainly internalized via receptor-mediated endocytosis. Therefore, tumors showing a poor expression of BLM-binding proteins are resistant to this therapy. Th...

Full description

Saved in:
Bibliographic Details
Published in2017 IEEE International Ultrasonics Symposium (IUS) p. 1
Main Authors Fix, Samantha M., Novell, Anthony, Escoffre, Jean-Michel, Tsuruta, James K., Dayton, Paul A., Bouakaz, Ayache
Format Conference Proceeding
LanguageEnglish
Published IEEE 01.09.2017
Subjects
Cancer
Drug delivery
Immune system
Suspensions
Tumors
Ultrasonic imaging
Online AccessGet full text

Cover

More Information
Summary:Bleomycin (BLM) is a promising chemotherapeutic that causes oxidative damage to DNA resulting in cell death. However, this non-permeant drug is mainly internalized via receptor-mediated endocytosis. Therefore, tumors showing a poor expression of BLM-binding proteins are resistant to this therapy. This work aims to demonstrate the ability to improve the intracellular accumulation and efficacy of BLM in resistant colorectal adenocarcinoma cells (HT-29) through sonoporation with a low-boiling point formulation of phase change contrast agents (PCCAs).
ISSN:1948-5727
DOI:10.1109/ULTSYM.2017.8092269